Moreover, <i>CDCA7</i> knockdown not only decreased drug resistance in breast cancer cells but also reduced metastasis, invasion, and tumorigenic ability <i>in vivo</i>, ultimately prolonging the survival of tumor-bearing mice.<h4>Conclusion</h4>CDCA7 drives breast cancer chemoresistance by transcriptionally activating a pro-survival autophagy program in DTP cells, nominating it as a promising therapeutic target. Here, CDCA7 is linked to breast carcinoma.